This reclassification primarily addresses methodological challenges in standardizing allele ratio assessment, the emerging role of measurable residual disease (MRD) dynamics in NPM1-mutated AML, and the therapeutic impact of targeted kinase inhibitors (Falini & Dillon, 2024). Here, NPM1 is linked to acute myeloid leukemia.